Clinical implication of biomarker for patients with acute stroke

晚期糖基化终产物受体（receptor for advanced glycation end products，sCRP）是一种分泌型的糖基化终产物受体，包括sCRP和内源性sCRP。戊糖甙是一种晚期糖基化终产物。凝集素样氧化LDL受体1负责氧化LDL的摄取，并部分以可溶形式（sLOX-1）释放至血清。很少有研究涉及AGEs-1系统或sLOX-1在急性卒中患者中的关键作用。我们测定了急性卒中患者血浆sLOX/esophthalidine、pentosidine和sLOX-1水平与临床特征的相关性。血浆雌二醇和雌二醇水平与估计的肾小球滤过率相关。急性脑卒中患者血浆戊糖甙水平高于正常人。戊糖甙的临界值114 pmol/mL对急性脑卒中具有较高的敏感性（0.798）和特异性（0.800）。sLOX-1在缺血性卒中发病后1周内检测到高水平，但在3个月时下降。

A secreted isoform of receptor for advanced glycation end products (sRAGE) involves sRAGE and endogenous sRAGE (esRAGE). Pentosidine is one of an advanced glycation end product (AGE). Lectin-like oxidized LDL receptor 1 is responsible for the uptake of oxidized LDL and is released to serum in part as the soluble form (sLOX-1). Few studies addressed the pivotal roles of the AGEs-RAGE system or sLOX-1 in acute stroke patients. We measured plasma sRAGE/esRAGE, pentosidine, and sLOX-1 levels associated with clinical features in acute stroke. Both plasma sRAGE and esRAGE levels correlated with estimated glomerular filtration rate. Higher levels of plasma pentosidine compared with normal were demonstrated in patients with acute stroke. The cut off value 114 pmol/mL of pentosidine has high sensitivity (0.798) and specificity (0.800) for acute stroke. High level of sLOX-1 was examined within a week after the onset of ischemic stroke, however, they decreased at 3 month.